目的 以实验室前期制备的葛根素磷脂复合物微乳及普通常规微乳，采用乳糜微粒阻断法研究葛根素与磷脂形成复合物后对葛根素微乳经淋巴转运的影响。方法 以乳糜微粒阻滞技术阻断药物经淋巴转运，HPLC法测定大鼠血浆中葛根素浓度，通过比较阻断组与未阻断组生物利用度来计算淋巴转运的比例。结果 葛根素磷脂复合物微乳的淋巴转运高于普通常规微乳，其淋巴转运比例分别为51.3%、40.6%，葛根素磷脂复合物微乳未阻断组和阻断组的AUC_0~12分别为（5.489±1.599）、（2.673±1.153）μg·h/mL，葛根素普通常规微乳的未阻断组和阻断组的AUC_0~12分别为（4.158±1.160）、（2.478±1.352）μg·h/mL。结论 葛根素与磷脂复合后能够提高葛根素淋巴转运效率，且12 h的生物利用度要高于普通常规微乳。

Objective To study the effects of puerarin-phospholipid complex on lymphatic transport absorption of puerarin microemulsion based on the puerarin-phospholipid complex microemulsion and conventional microemulsion prepared before. Methods The chylomicron flow blocking approach was used to block lymphatic transport of the microemulsion, and the concentration of puerarin in plasma was determined by HPLC. Bioavailability of puerarin inblocking groups and non-blocking groups were compared to calculate the proportion of puerarin absorbed by lymphatic transport. Results The lymphatic transport of puerarin-phospholipid complex microemulsion was higher than that of conventional microemulsion, and the lymphatic translocation ratio was 51.3% and 40.6%, respectively. The AUC_0-12 of puerarin-phospholipid complex microemulsion non-blocking and blocking groups were (5.489 ±1.599) μg·h/mL and (2.673 ±1.153) μg·h/mL, respectively; And AUC_0-12 of puerarin routine microemulsion non-blocking and blocking groups were (4.158 ±1.160) μg·h/mL and (2.478 ±1.352) μg·h/mL, respectively. Conclusion The lymphatic transport of puerarin-phospholipid complex microemulsion can increase lymphatic transport efficiency, and AUC_0-12 of which were higher than those of conventional microemulsion group.

湖南省科技计划项目（2016TP2002）